


ultrasound (IVUS) and coronary flow reserve (CFR) allow early detection and follow-up of TCAD.

Methods: We retrospectively reviewed pediatric heart recipients with TCAD. TCAD was diagnosed by angiography or IVUS. Patients transplanted at <6 months of age (infants) were compared to those transplanted at >6 months (children). Stable TCAD was defined as no change in severity after serial evaluation and progressive TCAD as worsening disease or death as a result of TCAD.

Results: Of 310 transplanted children, 52 (17%) were diagnosed with TCAD. Of those, 20 (38%) were infants and 32 (62%) were children at the time of transplantation. Age at TCAD diagnosis (8.3 ± 3.4 vs 14 ± 5.8 , $p < 0.001$) and the number of prior rejection episodes (3.3 ± 1.7 vs 5.8 ± 3.6 , $p < 0.01$) were significantly lower in the infant group. Nevertheless, infants with TCAD had significantly more episodes of rejection compared to those without TCAD (0.83 ± 1.14 vs 3.35 ± 1.73 , $p < 0.0001$). More patients in the children group had stable TCAD (76% vs 55%, $p < 0.01$), of those 9 (28%) were diagnosed by IVUS, compared to none in the infant group. Compared to children, infants had a longer time from transplantation to diagnosis of TCAD (8.0 ± 3.4 vs 5.4 ± 3 years, $p < 0.01$) but their angiographic score was higher at diagnosis (3 ± 1 vs 1.7 ± 1.3 , $p < 0.01$). Coronary flow reserve in the infant group was significantly lower (2.3 ± 0.5 vs 3 ± 0.3 , $p < 0.05$) at the time of TCAD diagnosis and showed a progressive decline over time compared to the children group (CFR 2 years post-TCAD diagnosis 2.1 ± 0.6 vs 2.9 ± 0.7 , $p < 0.01$). There was a trend towards shorter time from diagnosis of TCAD to death or retransplantation in the infant group (0.9 ± 0.9 vs 2.8 ± 3.4 years, $p = 0.06$).

Conclusion: TCAD in infant recipients is diagnosed later, appears worse by angiography and is associated with a lower CFR at the time of diagnosis which tends to decline over time. Despite fewer rejections in infant recipients with TCAD, there is a trend towards shorter time to death or retransplantation, reflecting a more aggressive nature of TCAD.



O10-4


Survival and follow-up after cardiac transplantation for congenital heart diseases.

Guillaume M.P., Timmermans T., Van Caeneghem O., Poncelet A., Gurné O., Carbonez K., Sluysmans T.
Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium

Introduction: The number of patients with congenital heart disorder requiring a cardiac transplant is limited. We report our experience concerning survival and complications of congenital patients after cardiac transplantation in our hospital.

Method: From 1985 to January 2010, 19 patients (9 children and 10 adults) were transplanted (7 single ventricle, 5 left heart valvular

disease (4 aortic and 1 mitral), 2 D-TGA after Senning or Mustard, 1 congenitally corrected transposed great arteries, 2 Fallot, 1 truncus, 1 complete AV canal. Median age at cardiac transplant was 20.8 years (min 7 years, max 64 year) after a medium delay on the waiting list of 135 days (min 7 days – max 3 years).



Results: Four patients died respectively after 1, 2, 6 days and 10 years post transplant. The rate of survival was 84% at 10 years and 74% at 20 years of follow-up. 1985–2010 – Survival Probability of Congenital. Patients after cardiac transplantation (n = 19)

Complications were acute rejection (n = 5) with 3 deaths at day 1, day 6 and 10 years post transplant, chronic renal insufficiency (14/15) with necessity of dialysis in 3 patients, infections (14/15; septicaemia n = 4, organ infection n = 6, local infection = 7), hypertension (11/15), arrhythmia (2/15, pacemaker 1/15), cerebral vascular accident (2/15), hyperlipidemia (14/15), dysthyroidia (5/15), diabetes (1/15), hyperuricemia (1/15), osteoporosis (3/15).

Conclusion: Survival and quality of life after cardiac transplant for congenital heart disease are globally good. Complications are nevertheless frequent, particularly renal insufficiency.

O10-5

More than ten years after heart transplantation in children

Di Filippo S. (1), Ducreux C. (1), Henaine R. (2), Boissonnat P. (3), Sebbag L. (3), Roussoulières A. (3), Gouton M. (1), Ninet J. (2), Sassolas F. (1), Bozio A. (1)

Pediatric Cardiology, Cardiovascular Hospital Louis Pradel, Lyon, France (1); Cardiac Surgery, Cardiovascular Hospital Louis Pradel, Lyon, France (2); Department of Heart Transplantation, Cardiovascular Hospital Louis Pradel, Lyon, France (3)

Mid-term outcomes of pediatric transplanted patients are reported to be favourable, but very long-term graft and patient survival is still a matter of debate. The aim of this study was to assess status and long-term outcome of children who completed at least 10 years follow-up after heart transplantation (HTx).

Material and methods: The records of patients <18 years old at HTx, who survived at least 10 years posttransplant, were reviewed for clinical, biological, echocardiographic and angiographic data.

Results: Since 1987, 91 patients less than 18 years of age, received a HTx. Among them, 27 (14 males) survived at least 10 years after transplant; the others either died (22) or had less than 10-year follow-up (42). Indication for HTx was congenital heart disease in 10 and cardiomyopathy in 17. Age at HTx was 10.3 ± 6.3 years (2 days to 17.8 years): 8 were aged <5 years, 5 were 5 to 10 years old and 14 were 10 to 18 years old. Follow-up was 16.2 ± 4.1 years (10 to 25.3). Four patients died at 11, 12 and 14 years posttransplant,